These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28235541)

  • 1. Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
    Gutteridge RE; Singh CK; Ndiaye MA; Ahmad N
    Cancer Lett; 2017 May; 394():13-21. PubMed ID: 28235541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.
    Schmit TL; Zhong W; Setaluri V; Spiegelman VS; Ahmad N
    J Invest Dermatol; 2009 Dec; 129(12):2843-53. PubMed ID: 19554017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
    Cholewa BD; Pellitteri-Hahn MC; Scarlett CO; Ahmad N
    J Proteome Res; 2014 Nov; 13(11):5041-50. PubMed ID: 24884503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.
    Posch C; Cholewa BD; Vujic I; Sanlorenzo M; Ma J; Kim ST; Kleffel S; Schatton T; Rappersberger K; Gutteridge R; Ahmad N; Ortiz/Urda S
    J Invest Dermatol; 2015 Oct; 135(10):2475-2483. PubMed ID: 26016894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.
    Zhang Z; Zhang G; Gao Z; Li S; Li Z; Bi J; Liu X; Li Z; Kong C
    BMC Cancer; 2017 Dec; 17(1):861. PubMed ID: 29246203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway.
    Kim HJ; Cho JH; Kim JR
    J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1145-56. PubMed ID: 23525475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
    Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of PLK1 inhibits invasion and promotes apoptosis in glioma cells through regulating autophagy.
    Wu ZY; Wei N
    Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2723-2733. PubMed ID: 29771424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.
    Su S; Chhabra G; Ndiaye MA; Singh CK; Ye T; Huang W; Dewey CN; Setaluri V; Ahmad N
    Mol Cancer Ther; 2021 Jan; 20(1):161-172. PubMed ID: 33177155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted PLK1 suppression through RNA interference mediated by high-fidelity Cas13d mitigates osteosarcoma progression via TGF-β/Smad3 signalling.
    Yuan Y; Cao D; Zhang A; Liu Z; Deng Z; Zhang S
    J Cell Mol Med; 2024 May; 28(10):e18400. PubMed ID: 38780513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
    Mok WC; Wasser S; Tan T; Lim SG
    World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN; Louwen F; Zimmer B; Yuan J
    Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
    Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
    Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region.
    Zhang J; Wang S; Kern S; Cui X; Danner RL
    J Biol Chem; 2007 Jan; 282(2):1003-9. PubMed ID: 17121839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
    Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polo-like kinase 1 (Plk1) in non-melanoma skin cancers.
    Schmit TL; Zhong W; Nihal M; Ahmad N
    Cell Cycle; 2009 Sep; 8(17):2697-702. PubMed ID: 19652546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic relevance of the protein phosphatase 2A in cancer.
    Cunningham CE; Li S; Vizeacoumar FS; Bhanumathy KK; Lee JS; Parameswaran S; Furber L; Abuhussein O; Paul JM; McDonald M; Templeton SD; Shukla H; El Zawily AM; Boyd F; Alli N; Mousseau DD; Geyer R; Bonham K; Anderson DH; Yan J; Yu-Lee LY; Weaver BA; Uppalapati M; Ruppin E; Sablina A; Freywald A; Vizeacoumar FJ
    Oncotarget; 2016 Sep; 7(38):61544-61561. PubMed ID: 27557495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.